

About PharmaMatrix — Boilerplate

About PharmaMatrix

PharmaMatrix Inc. is a clinical-stage biotechnology company developing a new generation of targeted oncology therapies based on selective microtubule disruption. Its lead asset, CCI-001, is in Phase 1 clinical evaluation in bladder cancer (NCT04823897) with expansion planned into breast cancer. The company holds composition-of-matter patents granted by the USPTO, CIPO and EPO. For more information visit pharmamatrix.com.

Please use this paragraph verbatim when describing the company.